Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...

This new treatment is a welcome addition ... However, not all patients derive adequate symptom coverage with currently available therapies. As a result, there remains a significant medical need for ...

Researchers at Case Western Reserve University have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and ...

New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical ...

A recent study from researchers at University Hospitals Connor Whole Health has shed light on the experiences and ...

A recent study from researchers at University Hospitals Connor Whole Health has shed light on the experiences and ...

In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...

Ali Parsa back in the news, just over one year after Babylon Health’s implosion. Babylon’s CEO/founder Ali Parsa has a new and stealthy AI-related venture called Quadrivia. It was announced, unusually ...

The appointment of Aston University’s new distinguished Regius Professor of Pharmacy is ... the analysis of the impact of ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

Study finds mosaicism in Down syndrome reduces Alzheimer's risk, providing new insights into genetic influences on cognitive ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...